AGL 6.90 Increased By ▲ 0.45 (6.98%)
ANL 9.77 Increased By ▲ 0.07 (0.72%)
AVN 76.82 Decreased By ▼ -0.78 (-1.01%)
BOP 5.49 Increased By ▲ 0.06 (1.1%)
CNERGY 5.05 Increased By ▲ 0.08 (1.61%)
EFERT 79.83 Increased By ▲ 2.58 (3.34%)
EPCL 57.48 Increased By ▲ 1.99 (3.59%)
FCCL 15.30 Decreased By ▼ -0.06 (-0.39%)
FFL 6.48 No Change ▼ 0.00 (0%)
FLYNG 7.34 Decreased By ▼ -0.13 (-1.74%)
GGGL 10.75 Increased By ▲ 0.30 (2.87%)
GGL 16.94 Increased By ▲ 0.55 (3.36%)
GTECH 8.30 Decreased By ▼ -0.07 (-0.84%)
HUMNL 6.45 No Change ▼ 0.00 (0%)
KEL 3.02 Increased By ▲ 0.09 (3.07%)
LOTCHEM 29.15 Increased By ▲ 0.81 (2.86%)
MLCF 28.30 Increased By ▲ 0.22 (0.78%)
OGDC 76.53 Increased By ▲ 2.68 (3.63%)
PAEL 15.87 Increased By ▲ 0.32 (2.06%)
PIBTL 5.43 Increased By ▲ 0.08 (1.5%)
PRL 17.69 Increased By ▲ 0.30 (1.73%)
SILK 1.08 Increased By ▲ 0.01 (0.93%)
TELE 10.82 Decreased By ▼ -0.14 (-1.28%)
TPL 8.60 Increased By ▲ 0.79 (10.12%)
TPLP 21.19 Increased By ▲ 1.53 (7.78%)
TREET 23.80 Decreased By ▼ -0.05 (-0.21%)
TRG 127.50 Increased By ▲ 0.60 (0.47%)
UNITY 23.10 Increased By ▲ 0.04 (0.17%)
WAVES 11.63 Increased By ▲ 0.08 (0.69%)
WTL 1.14 No Change ▼ 0.00 (0%)
BR100 4,174 Increased By 48.3 (1.17%)
BR30 15,806 Increased By 310.9 (2.01%)
KSE100 41,518 Increased By 366.7 (0.89%)
KSE30 15,562 Increased By 142.1 (0.92%)
World

EU Commission to end AstraZeneca and J&J vaccine contracts at expiry

  • It added that Brussels would rather focus on COVID-19 vaccines using messenger RNA (mRNA) technology, such as Pfizer's and Moderna's.
Published April 14, 2021
Follow us

MILAN: The EU Commission has decided not to renew COVID-19 vaccine contracts next year with companies such as Astrazeneca and Johnson & Johnson (J&J), Italian daily La Stampa reported on Wednesday citing a source from the Italian Health Ministry.

"The European Commission, in agreement with the leaders of many (EU) countries, has decided that the contracts with the companies that produce (viral vector) vaccines that are valid for the current year will not be renewed at their expiry," the newspaper reported.

It added that Brussels would rather focus on COVID-19 vaccines using messenger RNA (mRNA) technology, such as Pfizer's and Moderna's.

The European Commission is seeking clarification from J&J about the company's "completely unexpected" announcement of delays in COVID-19 vaccine deliveries to the EU, an EU official told Reuters on Tuesday.

Comments

Comments are closed.